|
1
|
Wallace MC, Preen D, Jeffrey GP and Adams
LA: The evolving epidemiology of hepatocellular carcinoma: A global
perspective. Expert Rev Gastroenterol Hepatol. 9:765–779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ngan CY, Yamamoto H, Takagi A, Fujie Y,
Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M,
Matsuura N, et al: Oxaliplatin induces mitotic catastrophe and
apoptosis in esophageal cancer cells. Cancer Sci. 99:129–139.
2008.
|
|
3
|
Abdel-Rahman O: Revisiting
oxaliplatin-based regimens for advanced hepatocellular carcinoma.
Curr Oncol Rep. 16:3942014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo
C, Yin L, Han Y, Cai C, Li Y, et al: BMP4 promotes oxaliplatin
resistance by an induction of epithelial-mesenchymal transition via
MEK1/ERK/ELK1 signaling in hepatocellular carcinoma. Cancer Lett.
411:117–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin X, Tang B, Li JH, Wang Y, Zhang L, Xie
XY, Zhang BH, Qiu SJ, Wu WZ and Ren ZG: ID1 promotes hepatocellular
carcinoma proliferation and confers chemoresistance to oxaliplatin
by activating pentose phosphate pathway. J Exp Clin Cancer Res.
36:1662017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sheng J, Shen L, Sun L, Zhang X, Cui R and
Wang L: Inhibition of PI3K/mTOR increased the sensitivity of
hepatocellular carcinoma cells to cisplatin via interference with
mitochondriallysosomal crosstalk. Cell Prolif. 52:e126092019.
View Article : Google Scholar
|
|
7
|
Morandi A and Indraccolo S: Linking
metabolic reprogramming to therapy resistance in cancer. Biochim
Biophys Acta Rev Cancer. 1868:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fekir K, Dubois-Pot-Schneider H, Désert R,
Daniel Y, Glaise D, Rauch C, Morel F, Fromenty B, Musso O, Cabillic
F, et al: Retrodifferentiation of human tumor hepatocytes to stem
cells leads to metabolic reprogramming and chemoresistance. Cancer
Res. 79:1869–1883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choiniere J, Wu J and Wang L: Pyruvate
dehydrogenase kinase 4 deficiency results in expedited cellular
proliferation through E2F1-mediated increase of cyclins. Mol
Pharmacol. 91:189–196. 2017. View Article : Google Scholar :
|
|
10
|
Dai Y, Xiong X, Huang G, Liu J, Sheng S,
Wang H and Qin W: Dichloroacetate enhances adriamycin-induced
hepatoma cell toxicity in vitro and in vivo by increasing reactive
oxygen species levels. PLoS One. 9:e929622014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X,
Xie L, Yang J, Yu H, Su J, et al: ABT737 reverses cisplatin
resistance by targeting glucose metabolism of human ovarian cancer
cells. Int J Oncol. 53:1055–1068. 2018.PubMed/NCBI
|
|
12
|
Saunier E, Benelli C and Bortoli S: The
pyruvate dehydrogenase complex in cancer: An old metabolic
gatekeeper regulated by new pathways and pharmacological agents.
Int J Cancer. 138:809–817. 2016. View Article : Google Scholar
|
|
13
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Gatter KC and Harris AL; Tumor and Angiogenesis Research Group:
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression
in non small cell lung cancer and tumor-associated stroma.
Neoplasia. 7:1–6. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Liu F, Ao P, Li X, Zheng H, Wu D,
Zhang N, She J, Yuan J and Wu X: Correlation of PDK1 expression
with clinico-pathologic features and prognosis of hepatocellular
carcinoma. OncoTargets Ther. 9:5597–5602. 2016. View Article : Google Scholar
|
|
15
|
Battello N, Zimmer AD, Goebel C, Dong X,
Behrmann I, Haan C, Hiller K and Wegner A: The role of HIF-1 in
oncostatin M-dependent metabolic reprogramming of hepatic cells.
Cancer Metab. 4:32016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W, Su J, Xu H, Yu S, Liu Y, Zhang Y,
Sun L, Yue Y and Zhou X: Dicumarol inhibits PDK1 and targets
multiple malignant behaviors of ovarian cancer cells. PLoS One.
12:e01796722017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC: Drug combination studies and
their synergy quantifi-cation using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rodea-Palomares I, Petre AL, Boltes K,
Leganés F, Perdigón-Melón JA, Rosal R and Fernández-Piñas F:
Application of the combination index (CI)-isobologram equation to
study the toxicological interactions of lipid regulators in two
aquatic bioluminescent organisms. Water Res. 44:427–438. 2010.
View Article : Google Scholar
|
|
19
|
Xu H, Sun L, He Y, Yuan X, Niu J, Su J and
Li D: Deficiency in IL-33/ST2 Axis Reshapes Mitochondrial
Metabolism in Lipopolysaccharide-Stimulated Macrophages. Front
Immunol. 10:1272019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Y, Meng H, Xu H, Fan L, Zhou Z, Xu B,
Sun L and Gao Y: Regulation of integrated stress response
sensitizes U87MG glioblastoma cells to temozolomide through the
mitochondrial apoptosis pathway. Anat Rec (Hoboken). 301:1390–1397.
2018. View Article : Google Scholar
|
|
21
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45(W1):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen
ZL, Li G, Bi ZY, Bi YY, Gong FY, et al: Transcriptional E2F1/2/5/8
as potential targets and transcriptional E2F3/6/7 as new biomarkers
for the prognosis of human lung carcinoma. Aging (Albany NY).
10:973–987. 2018. View Article : Google Scholar
|
|
23
|
Lian Q, Wang S, Zhang G, Wang D, Luo G,
Tang J, Chen L and Gu J: HCCDB: A Database of Hepatocellular
Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics.
16:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Emmanouilidi A and Falasca M: Targeting
PDK1 for Chemosensitization of Cancer Cells. Cancers (Basel).
9:92017. View Article : Google Scholar
|
|
25
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang W, Zhang SL, Hu X and Tam KY:
Targeting tumor metabolism for cancer treatment: is pyruvate
dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol
Sci. 11:1390–1400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhattacharya B, Mohd Omar MF and Soong R:
The Warburg effect and drug resistance. Br J Pharmacol.
173:970–979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ngoi NYL, Eu JQ, Hirpara J, Wang L, Lim
JSJ, Lee SC, Lim YC, Pervaiz S, Goh BC and Wong ALA: Targeting cell
metabolism as cancer therapy. Antioxid Redox Signal. 32:285–308.
2020. View Article : Google Scholar
|
|
29
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amoedo ND, Obre E and Rossignol R: Drug
discovery strategies in the field of tumor energy metabolism:
Limitations by metabolic flexibility and metabolic resistance to
chemotherapy. Biochim Biophys Acta Bioenerg. 1858:674–685. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shin YK, Yoo BC, Hong YS, Chang HJ, Jung
KH, Jeong SY and Park JG: Upregulation of glycolytic enzymes in
proteins secreted from human colon cancer cells with 5-fluorouracil
resistance. Electrophoresis. 30:2182–2192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo W, Zhang Y, Chen T, Wang Y, Xue J,
Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of
pyruvate kinase M2 combined with cisplatin in a lung cancer model.
J Cancer Res Clin Oncol. 137:65–72. 2011. View Article : Google Scholar
|
|
33
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jeoung NH: Pyruvate Dehydrogenase Kinases:
Therapeutic Targets for Diabetes and Cancers. Diabetes Metab J.
39:188–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qin L, Tian Y, Yu Z, Shi D, Wang J, Zhang
C, Peng R, Chen X, Liu C, Chen Y, et al: Targeting PDK1 with
dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell
growth. Oncotarget. 7:1395–1407. 2016. View Article : Google Scholar :
|
|
36
|
Wada M, Horinaka M, Yasuda S, Masuzawa M,
Sakai T and Katoh N: PDK1 is a potential therapeutic target against
angiosarcoma cells. J Dermatol Sci. 78:44–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang
D, Lv H, Tang S, Jin N, Jiang H, et al: JX06 Selectively inhibits
pyruvate dehydrogenase kinase PDK1 by a covalent cysteine
modification. Cancer Res. 75:4923–4936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tataranni T and Piccoli C: Dichloroacetate
(DCA) and cancer: An overview towards clinical applications. Oxid
Med Cell Longev. 2019:82010792019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stacpoole PW, Martyniuk CJ, James MO and
Calcutt NA: Dichloroacetate-induced peripheral neuropathy. Int Rev
Neurobiol. 145:211–238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stacpoole PW: The pharmacology of
dichloroacetate. Metabolism. 38:1124–1144. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu X, Zhou D, Hou B, Liu QX, Chen Q, Deng
XF, Yu ZB, Dai JG and Zheng H: Dichloroacetate enhances the
antitumor efficacy of chemotherapeutic agents via inhibiting
autophagy in non-small-cell lung cancer. Cancer Manag Res.
10:1231–1241. 2018. View Article : Google Scholar : PubMed/NCBI
|
